DRI Healthcare Trust (DHT.UN) Stock Price, News & Analysis

Company Overview

DRI Healthcare Trust is an open-ended trust that provides unitholders with differentiated exposure to the anticipated growth in the global pharmaceuticals and biotechnology markets. Its business model is focused on managing and growing a diversified portfolio of pharmaceutical royalties to deliver attractive growth in cash royalty receipts over the long term. Geographically, it has a presence in the United States; European Union; Japan, and Rest of the world.

Key Stats

• Today's Range: C$12.95 to C$13.01
• 50-Day Range: C$10.85 to C$13.21
• 52-Week Range: C$10.39 to C$16.26
• Volume: 8,400 shs
• Average Volume: 42,450 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: 3.54%
• Price Target: C$18.07
• Consensus Rating: Moderate Buy

DHT.UN Stock Analysis - Frequently Asked Questions

How have DHT.UN shares performed this year?

DRI Healthcare Trust's stock was trading at C$11.83 at the beginning of the year. Since then, DHT.UN shares have increased by 9.7% and is now trading at C$12.98.
View the best growth stocks for 2025 here.

How do I buy shares of DRI Healthcare Trust?

Shares of DHT.UN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: TSE:DHT.UN
• CIK: N/A
• Web: www.dricapital.com
• Phone: 416-863-1865
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: C$18.07
• High Stock Price Target: C$22.00
• Low Stock Price Target: C$14.00
• Potential Upside/Downside: +39.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): C($0.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 20.43
• P/E Growth: N/A
• Net Income: C$9.73 million
• Net Margins: 5.02%
• Pretax Margin: N/A
• Return on Equity: 2.06%
• Return on Assets: 4.22%

Debt

• Debt-to-Equity Ratio: 63.20
• Current Ratio: 1.36
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: C$193.66 million
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: C$9.32 per share
• Price / Book: 1.39

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: N/A
• Beta: 0.60